Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Joseph C. Scodari Acquires 24,631 Shares

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Joseph C. Scodari bought 24,631 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were purchased at an average cost of $1.01 per share, for a total transaction of $24,877.31. Following the acquisition, the director now directly owns 27,708 shares in the company, valued at $27,985.08. This trade represents a 800.49 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Acurx Pharmaceuticals Stock Performance

Acurx Pharmaceuticals stock traded down $0.06 during midday trading on Wednesday, reaching $0.75. 1,695,648 shares of the stock were exchanged, compared to its average volume of 877,882. The company’s fifty day moving average is $1.21 and its 200-day moving average is $1.79. The firm has a market cap of $12.69 million, a PE ratio of -0.69 and a beta of -1.71. Acurx Pharmaceuticals, Inc. has a 52 week low of $0.68 and a 52 week high of $5.28.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter in the prior year, the business posted ($0.24) earnings per share. On average, sell-side analysts anticipate that Acurx Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Acurx Pharmaceuticals in a report on Tuesday, December 10th.

Hedge Funds Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Geode Capital Management LLC raised its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 12.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 146,500 shares of the company’s stock after buying an additional 16,485 shares during the period. Geode Capital Management LLC owned about 0.90% of Acurx Pharmaceuticals worth $278,000 at the end of the most recent quarter. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.